Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Zigao Yuan, Shaopeng Chen, Qinsheng Sun, et al.
Bioorganic & Medicinal Chemistry (2017) Vol. 25, Iss. 15, pp. 4100-4109
Closed Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li, Yang Yang, Weiqi Hong, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1391
Xenograft and organoid model systems in cancer research
Margit Bleijs, Marc van de Wetering, Hans Clevers, et al.
The EMBO Journal (2019) Vol. 38, Iss. 15
Open Access | Times Cited: 327
Dual or multi-targeting inhibitors: The next generation anticancer agents
Nulgumnalli Manjunathaiah Raghavendra, Divya Pingili, Sundeep Kadasi, et al.
European Journal of Medicinal Chemistry (2017) Vol. 143, pp. 1277-1300
Closed Access | Times Cited: 248
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 86
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Dongha Kim, Hye Jin Nam
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8412-8412
Open Access | Times Cited: 71
Design, Synthesis, and Structure–Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition
Ji‐Long Duan, Chenchen Wang, Yinghui Yuan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4950-4976
Closed Access | Times Cited: 36
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu, Yichao Wan, Yuliang Xiao, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8977-9002
Closed Access | Times Cited: 130
Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer
Heba M. Hesham, Deena S. Lasheen, Khaled A. M. Abouzid
Medicinal Research Reviews (2018) Vol. 38, Iss. 6, pp. 2058-2109
Closed Access | Times Cited: 128
Fanconi Anemia Signaling and Cancer
Manoj Nepal, Raymond Che, Jun Zhang, et al.
Trends in cancer (2017) Vol. 3, Iss. 12, pp. 840-856
Open Access | Times Cited: 97
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Xiaopeng Peng, Zhiqiang Sun, Peihua Kuang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112831-112831
Closed Access | Times Cited: 92
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Amr K. A. Bass, Mona S. El‐Zoghbi, El-Shimaa M. Nageeb, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112904-112904
Closed Access | Times Cited: 79
Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
Rubi Roy, Tasnim Ria, Debapriya RoyMahapatra, et al.
ACS Omega (2023) Vol. 8, Iss. 19, pp. 16532-16544
Open Access | Times Cited: 29
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Qingyun Zhu, Qiuzi Dai, Lei Zhao, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 11
Designing an anticancer Pd(II) complex as poly(ADP-ribose) polymerase 1 inhibitor
Shuangshuang Gai, Peng Cao, Xuwei Zhong, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139885-139885
Closed Access | Times Cited: 1
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Rekha Sangwan, Remya Rajan, Pintu Kumar Mandal
European Journal of Medicinal Chemistry (2018) Vol. 158, pp. 620-706
Closed Access | Times Cited: 79
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8827-8869
Closed Access | Times Cited: 46
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 22
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions
Denys Bondar, Yevgen Karpichev
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1269-1269
Open Access | Times Cited: 8
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Two-hit wonders: The expanding universe of multitargeting epigenetic agents
Ángel R. de Lera, A. Ganesan
Current Opinion in Chemical Biology (2020) Vol. 57, pp. 135-154
Closed Access | Times Cited: 40
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective
Jiahui Zhang, Jin Zhang, Hua Li, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103607-103607
Closed Access | Times Cited: 14
Drug conjugates—an emerging approach to treat breast cancer
Mahmud Hasan, Rehana K. Leak, Robert E. Stratford, et al.
Pharmacology Research & Perspectives (2018) Vol. 6, Iss. 4
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top